QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma
- 2020年08月13日 16:30:00
- テクノロジー
- JCN Newswire
Dr Victoria Gordon, Managing Director and CEO of QBiotics, said, "We are delighted to announce this collaboration with MSD. Patients with unresectable melanoma who have received prior checkpoint inhibitors currently have limited effective treatment options. Through this program we hope to see that when combined, tigilanol tiglate and Keytruda may produce additive anti-tumour immune responses, and improve outcomes for patients."
The Phase I/II open label 'QBC46-H06'study is a dose escalation and expansion study with the primary objective of determining the maximum tolerated dose or maximum feasible dose of the combination therapy. Secondary measures include assessing tumour responses in both injected tumours and uninjected tumours, as well as clinical efficacy parameters. Patients with unresectable melanoma and who have had exposure to immune checkpoint inhibitors are eligible for the study.
Dr Gordon continued, "This study follows on from encouraging Phase I data where tigilanol tiglate as a monotherapy showed a 27% treatment response rate*, including an 18% complete response with full tumour destruction across a wide variety of solid tumour types(2). Two patients with melanoma that had complete responses also had an abscopal (anenestic) response. Melanoma is the second human application we are pursuing for tigilanol tiglate following on from our Phase I/II clinical trial in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) which commenced in December 2019".
Tigilanol tiglate is a small molecule administered by intratumoural injection directly into the solid tumour mass. Once injected, it has a multi-modal action including (i) rapid, but highly localised, inflammatory responses, (ii) increased permeability and destruction of tumour vascular endothelium, and (iii) rapid tumour cell death by oncosis(1).
*27% treatment response rate (n=6);18% complete response rate (n=4)2.
Issued by QBiotics Group Limited - www.qbiotics.com
For further information
Dr Victoria Gordon, CEO &Managing Director, QBiotics Group
victoria.gordon@qbiotics.com or + 61 418 453 737
For media enquiries
Jane Lowe, IR Department
jane.lowe@irdepartment.com.au or +61 411 117 774
About QBiotics
QBiotics is a public unlisted Australian life sciences company which discovers, develops and commercialises novel anticancer and wound healing products for human and veterinary markets. Its lead product, tigilanol tiglate, is an anticancer pharmaceutical targeting a range of solid tumours across multiple species. QBiotics'business model is to develop products that have application in both veterinary and human markets. Success in the veterinary programs validates QBiotics technology and de-risks human development, while generating early, non-diluting revenues. https://qbiotics.com
About Tigilanol tiglate
Tigilanol tiglate is a small molecule that is being tested as an intratumoural treatment for solid tumours. Its effect on tumours is multimodal and involves injected tumour responses as well as distal responses in non-injected tumours. Complete destruction of the injected tumour is mediated via tumour vascular disruption as well as death of tumour cells by oncosis1. Following tumour destruction, rapid wound healing has been shown to ensue.
A single injection of tigilanol tiglate has been shown in canine patients to ablate (completely destroy) 75% of treated tumours(3). Veterinary use of tigilanol tiglate (branded STELFONTA(R)) has received marketing authorisation by the European Medicines Authority and the Veterinary Medicines Directorate in the United Kingdom as a treatment for canine mast cell tumours. STELFONTA(R) is also under review by the US Food and Drug Administration - Center for Veterinary Medicine and the Australian Pesticides and Veterinary Medicines Authority. STELFONTA(R) is partnered with Virbac, a global animal health company and launched in Europe in April 2020.
References
1. Boyle et al., (2014) Intra-tumoural injection of the novel PKC activator EBC-46 rapidly ablates tumours in mouse models. PLoS One 9:e1068887. DOI: 10.1371/journal.pone.0108887.
2. Panizza et al., (2019) Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intra tumoural injection of tigilanol tiglate (EBC-46). EBioMedicine 50: 433-441.
3. De Ridder et al., (2020). Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). Journal of Veterinary Internal Medicine. 1-15. DOI: 10.1111/jvim.15806
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com
重要指名手配の上地恵栄容疑者が死亡 2005年の三鷹殺人事件
本田圭佑がアルビレックス新潟シンガポールに練習参加 真剣な表情で汗を流し若手にメッセージも
【阪神】岡田監督、4失策「出たら一気に出るなあ」坂本犠打失敗は「クソボールやろ」/一問一答
【阪神】15連続試合被本塁打なしで2リーグ制後球団新! セでは50年中日の17試合が最長
アンミカ「届いたら興奮して寝られへん」大谷翔平の寝具マット約2500枚無償提供に言及
【DeNA】三度目の正直でライブ開催! 浅岡雄也が試合後に「突然」など熱唱して盛り上げ
JR東海道線 人身事故で一時運転見合わせ、再開
【韓国ヨーグルト「ビヨット」新大久保で買える!】食べ歩き用も新登場!どこで買える?
【巨人】戸郷翔征、逆転許したルーキーかばう「腐らずにやってくれると」4回には足に打球当たる
ゆたぼん「ついに僕も高校生」甲子園7度出場名門校の通信課程に進学報告、公立高不合格から一転
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
完全にダマされた! 『ラヴィット!』あのちゃん“事故レベル”大暴走は『水ダウ』遠隔操作のしわざだった ネットも納得
小澤征悦と再婚した桑子真帆アナ(34)黒い過去が流出、衝撃の過去にネット騒然
大原櫻子、ガーシー暴露後初のSNS投稿に賛否の声「イメージ最悪になった」
ガーシー、またも綾野剛の暴露写真でネット歓喜「この写真見て笑っちゃう」
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
30キロ減量の華原朋美、痩せた美貌で“ノリノリ動画”公開 美ボディーで熱唱
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
辞退表明の元モー娘。市井氏が「初当選」 1日で辞職も7万円支給へ
大久保佳代子「30代前半は性欲おばけ」“ストッパー”にするためあえてしていたこと明かす
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
曙と熱愛した相原勇(52)の現在が衝撃的すぎると話題に
深夜のファミリーマート徘徊、必ず入っている「フエラムネのミニチュアおもちゃ付」を探し求めた結果……
ガーシー、佐野ひなこの暴露を示唆でネット騒然「ファンだったのに」
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
ガーシー、またも綾野剛の暴露写真でネット歓喜「この写真見て笑っちゃう」
いなば食品のホームページが表示されない!そして「プレスリリース」もヤバすぎると話題に
完全にダマされた! 『ラヴィット!』あのちゃん“事故レベル”大暴走は『水ダウ』遠隔操作のしわざだった ネットも納得
小澤征悦と再婚した桑子真帆アナ(34)黒い過去が流出、衝撃の過去にネット騒然
重要指名手配の上地恵栄容疑者が死亡 2005年の三鷹殺人事件
本田圭佑がアルビレックス新潟シンガポールに練習参加 真剣な表情で汗を流し若手にメッセージも
【阪神】岡田監督、4失策「出たら一気に出るなあ」坂本犠打失敗は「クソボールやろ」/一問一答
【阪神】15連続試合被本塁打なしで2リーグ制後球団新! セでは50年中日の17試合が最長
【DeNA】三度目の正直でライブ開催! 浅岡雄也が試合後に「突然」など熱唱して盛り上げ
アンミカ「届いたら興奮して寝られへん」大谷翔平の寝具マット約2500枚無償提供に言及
JR東海道線 人身事故で一時運転見合わせ、再開
【韓国ヨーグルト「ビヨット」新大久保で買える!】食べ歩き用も新登場!どこで買える?
【巨人】戸郷翔征、逆転許したルーキーかばう「腐らずにやってくれると」4回には足に打球当たる
ゆたぼん「ついに僕も高校生」甲子園7度出場名門校の通信課程に進学報告、公立高不合格から一転